(Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the positive outcome of its ...

There are strict rules around reporting a whole range of common health complaints affecting millions of people ...

Non-exclusive license providing Solid’s proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a full-service cell and gene ...

Some cats wobble, fall over constantly, and generally have no control over their movements. These cats live with the ...

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on ...

Biohaven Ltd. narrows focus to three late-stage clinical programs and implements cost-cutting to address heavy R&D spending.

FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) ...

ClearPoint Neuro, Inc. ( CLPT) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST [Audio Gap] comments made on this call may include statements that are forward-looking within the meaning of ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or BioMarin Pharmaceutical Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Non-exclusive license providing Solid's proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a full-service cell and gene therapy Contract Development and Manufacturing Organizatio ...

Mike: So, this technique was actually researched and tried by our own Bob Schrupp because his balance is compromised a bit ...